Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions

NCT06801015 · clinicaltrials.gov ↗

PHASE4

Phase

ACTIVE_NOT_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Obesity

Interventions

DRUG: Semaglutide
DRUG: Tirzepatide
DRUG: Placebo

Sponsor

Mayo Clinic